Prolastin c 1,000 MG/20 ML VLS
Ended Awarded
- Contract number
- SPE2DB26FWURW
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,084
Award facts
- Contract value 100% obligated
- $24,084.02 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $24,084.02 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of November 19, 2025, and was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) established through the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical supply support to Department of Defense medical facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial federal contracting activity as a critical supplier within the military pharmaceutical supply chain, with numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division. The company's product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables supporting diverse therapeutic categories. The underlying PPV-G GEN V contract, valued at up to $499,999,999 with a completion date of December 31, 2036, establishes a 30-month base period with three additional 30-month option periods, positioning DMS Pharmaceutical Group as a regional prime vendor contractor capable of fulfilling the specialized pharmaceutical requirements of the federal military medical system on a global basis.
Quick answers
Who was awarded contract SPE2DB26FWURW?
SPE2DB26FWURW was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 28, 2025.
How much is contract SPE2DB26FWURW worth?
The government has obligated $24,084 on SPE2DB26FWURW.
Is contract SPE2DB26FWURW an order under another contract?
Yes. SPE2DB26FWURW is a delivery order under SPE2DB25D9312, an indefinite delivery contract.
Was contract SPE2DB26FWURW competed?
The extent of competition for SPE2DB26FWURW was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award